Johnson & Johnson Invests Over $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced plans to invest more than $1 billion to build a new cell therapy manufacturing facility in Lower Gwynedd Township near its Spring House campus in Montgomery County, Pennsylvania. The plant is expected to create about 500 jobs when fully operational in 2031.

The facility will focus on producing advanced cell therapies for cancer treatment, including therapies targeting multiple myeloma, a cancer that affects white blood cells in bone marrow. Cell therapy uses engineered immune cells to fight disease, one of the fastest-growing areas in medicine. The new facility will further expand the company's US manufacturing capacity as it advances its portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.

The project will generate substantial employment during both construction and operations. More than 4,000 construction roles are expected to be supported during development, with over 500 skilled biomanufacturing jobs planned once the facility becomes fully operational. The plant is expected to serve thousands of patients annually while helping reduce costs and speed up delivery timelines for personalized therapies.

The investment forms part of the company's previously disclosed commitment to spend $55 billion across the US on manufacturing, research and development, and technology by early 2029. The new plant supports Johnson & Johnson's stated objective of manufacturing the majority of its advanced medicines within the US to meet domestic patient demand.

Pennsylvania is offering $41.5 million in support for the project. The CEO stated that by uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with communities, the company is delivering for patients and creating significant opportunities for workers and families.

The investment builds on Johnson & Johnson's deep roots in Montgomery County. Its Spring House research campus already employs roughly 2,500 scientists and serves as the company's largest R&D center. The company currently operates ten sites across Pennsylvania covering more than 2 million square feet of manufacturing, research, distribution and office space. Johnson & Johnson estimates its annual economic impact in Pennsylvania at approximately $10 billion.

The announcement comes amid a wave of pharmaceutical expansion across the region, including new projects by Eli Lilly, GSK, and Merck. Montgomery County is already one of the nation's top counties for pharmaceutical jobs.